The MMP-2-735 C allele is a risk factor for susceptibility to breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6199-6203

  Yari, Kheirollah ^a   Rahimi, Ziba ^a   Moradi, Mohamad Taher ^a   Rahimi, Zohreh ^a,b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Gene polymorphism; MMP 2 C 735T; Western Iran

Indexed keywords

GELATINASE A; MMP2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; IRAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SECONDARY; TUMOR INVASION; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84906281848     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6199     Document Type: Article

References (26)

1. Babu GR, Samari G, Cohen SP, et al (2011) Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev, 12, 1647-55.
2. Boroujeni HR, Karimi M, Moshkelani S, Parsaei P (2013) Association of the p53 codon 72 polymorphism with breast cancer in central part of Iran. African J Pharm Pharmacol, 7, 356-9.
3. Gai X, Zhang Z, Liang Y, et al (2010). MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin Chim Acta, 411, 719-24.
4. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, et al (2012). Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer, 12, 121.
5. Guo X-T, Wang J-F, Zhang L-Y, Xu G-Q (2012). Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pac J Cancer Prev, 13, 2853-6.
6. Hajihoseini S, Bahmani MK, Khosravi A, Ghezelsofla E, Ghaderi A (2011). Prognostic significance of MMP2 and MMP9 functional promoter single nucleotide polymorphisms in head and neck squamous cell carcinoma. Iran J Basic Med Sci, 14.
7. Hughes S, Agbaje O, Bowen RL, et al (2007). Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clinical Cancer Research, 13, 6673-80.
8. Ke P, Wu Z-D, Wen H-S, et al (2013). Current evidence on associations between the MMP-7 (-181A> G) polymorphism and digestive system cancer risk. Asian Pac J Cancer Prev, 14, 2269-72.
9. Rahimi M, Hasanvand A, Rahimi Z, et al (2010). Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro-and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem, 43, 1333-9.
10. Rahimi Z, Rahimi Z, Shahsavandi MO, Bidoki K, Rezaei M (2013). MMP-9 (-1562 C: T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia. Biomark Med, 7, 93-8.
11. Rahimi Z, Rahimi Z, Aghaei A, Vaisi-Raygani A (2014). AT2R-1332 G: A polymorphism and its interaction with AT1R 1166 A: C, ACE I/D and MMP-9-1562 C: T polymorphisms: Risk factors for susceptibility to preeclampsia. Gene, 538, 176-81.
12. Rahimi Z, Vaisi Raygani A, Merat A, et al (2006). Thalassemic mutations in southern Iran. Iranian J Med Sci (IJMS), 31, 70-3.
13. Saeed HM, Alanazi MS, Parine NR, et al (2013). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the Saudi population. Asian Pac J Cancer Prev, 14, 6025-6030.
14. Sanii S, Saffar H, Tabriz HM, et al (2012). Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pac J Cancer Prev, 13, 2175-8.
15. Shagisultanova EI, Novikova IA, Sidorenko YS, et al (2004). The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res, 24, 199-202.
16. Sharma KL, Misra S, Kumar A, Mittal B (2012). Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int, 32, 1278-86.
17. Srivastava P, Kapoor R, Mittal RD (2013a). Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India, Urol Oncol, 31, 247-54.
18. Srivastava P, Pandey S, Mittal B, Mittal RD (2013b). No Association of matrix metalloproteinase [MMP]-2 (-735C> T) and tissue inhibitor of metalloproteinase [TIMP]-2 (-418G> C) gene polymorphisms with cervical cancer susceptibility. Indian J Clin Biochem, 28, 13-8.
19. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70.
20. Wang F, Jin X-P, Zhu M, et al (2011). Genotype association of C (-735) T polymorphism of the MMP-2 gene with the risk of carotid atherosclerosis-vulnerable plaque in the Han Chinese population. Vasc Med, 16, 13-18.
21. Yadav L, Puri N, Rastogi V, et al (2014). Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085.
22. Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-8.
23. Zhang Y, Gu Z, Qiu G (2013). Association of the polymorphism of MMP2 with the risk and severity of lumbar disc degeneration in the Chinese Han population. Eur Rev Med Pharmacol Sci, 17, 1830-4.
24. Zheng L, Zhang Y-M, Zhan Y-Z, Liu C-X (2014). Momordica cochinchinensis seed extracts suppress migration and invasion of human breast cancer ZR-75-30 cells via downregulating MMP-2 and MMP-9. Asian Pac J Cancer Prev, 15, 1105.
25. Zhou P, Du L-F, Lv G-Q, et al (2011) Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 127, 813-8.
26. Zhou Y, Yu C, Miao X, et al (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis, 25, 399-404.